Daniela Maria Capuano1,3, Rosanna Cipolla3 and Roberto Verna1-3*
1World Association of Societies of Pathology and Laboratory Medicine, IL, USA
2UniCamillus University, Rome, Italy
3Center for Sports Medicine and Management, Sapienza University of Rome, Italy
*Corresponding Author: Roberto Verna, World Association of Societies of Pathology and Laboratory Medicine, IL, USA and UniCamillus University, Center for Sports Medicine and Management, Sapienza University of Rome, Italy.
Received: July 30, 2020; Published: September 28, 2020
With recent advances in DNA sequencing (high-throughput analysis), researchers have been able to examine epigenetic changes across the whole genome, and recent studies have shown that epigenetics play a central role in many types of diseases. Epigenetic variations have been found in various pathologies and their involvement in the cancerous transformation has been demonstrated. Given that epigenetic dysregulation is potentially reversible and given that many diseases have an epigenetic etiology, the researchers hypothesized that inhibition epigenetic changes may have therapeutic potential. This is what has encouraged the development of new pharmacological opportunities that can be defined with the term "epigenetic therapy". A number of epigenetic drugs have already been approved or are currently undergoing clinical trials. This paper is a review of the literature to illustrate the therapeutic potential of these drugs and evaluate their clinical application.
Keywords: DNA Sequencing; Epigenetic Therapy; Epigenetic Dysregulation
Citation: Roberto Verna., et al. “Strategic Therapies with Epigenetic Drugs: A Review". Acta Scientific Pharmaceutical Sciences 4.10 (2020): 100-119.
Copyright: © 2020 Roberto Verna., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.